---
title: "Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Clinical evidence"
description: "Formulary evidence on Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Clinical evidence. Covers NORSE TWO, NORSE EIGHT, NORSE ONE, NORSE THREE, and NORSE SEVEN. 82 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/clinical-evidence"
published: "2026-09-28T12:24:10-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 NORSE TWO

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Pivotal efficacy and safety trial supporting the nAMD indication

> “The efficacy of LYTENAVA for the treatment of neovascular (wet) age-related macular degeneration (nAMD) was demonstrated in a randomized, multi-center, masked, active-controlled study (NORSE TWO – NCT03834753).”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

> “This was a prospective multicenter, randomized, double-masked, active-controlled study, the aim of which was to demonstrate the efficacy and safety of intravitreal ONS-5010 (bevacizumab-vikg) in eyes with neovascular age-related macular degeneration (nAMD). This was a phase III trial on ONS-5010 (NORSE TWO).”

Source: [Rahhal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39535413/)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Summary: number of trial sites

The company's own announcement of the 12-month NORSE TWO results described the trial as enrolling 228 subjects across 39 clinical trial sites in the United States.

Source: [Outlook Therapeutics NORSE TWO 12-month safety results press release (2021)](https://www.globenewswire.com/news-release/2021/09/28/2304422/0/en/Outlook-Therapeutics-Reports-New-Positive-12-Month-Safety-Data-from-Pivotal-Phase-3-NORSE-TWO-Trial.html)

<a id="topic-3.1.1.2-2"></a>

###### NORSE TWO trial dates and location

| Field | Quoted record |
| --- | --- |
| Study Start Date | “2019-06-25” |
| Primary Completion Date | “2021-06-07” |
| Study Completion Date | “2021-07-08” |
| Overall Status | “Completed” |
| Country | “United States” |

Source: [ClinicalTrials.gov NCT03834753](https://clinicaltrials.gov/study/NCT03834753)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### NORSE TWO study design

> “A Clinical Effectiveness, Multicenter, Randomized, Double-masked, Controlled Study of the Efficacy and Safety of ONS-5010 in Subjects With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration”

Source: [ClinicalTrials.gov NCT03834753](https://clinicaltrials.gov/study/NCT03834753)

| Field | Quoted record |
| --- | --- |
| Allocation | “Randomized” |
| Intervention Model | “Parallel Assignment” |
| Masking | “Double” |
| Who Masked | “Participant”, “Outcomes Assessor” |
| Primary Purpose | “Treatment” |
| Phase | “Phase 3” |
| Enrollment | “228” |

Source: [ClinicalTrials.gov NCT03834753](https://clinicaltrials.gov/study/NCT03834753)

> “In NORSE TWO, adult patients with nAMD were randomized to LYTENAVA 1.25 mg (N=113) administered once monthly for 1 year or ranibizumab 0.5 mg (N=115) administered once monthly for 3 months (Days 0, 30, and 60) followed by once every 3 months for 1 year (Days 150 and 240). Patient ages ranged from 54 to 98 years, with a median age of 79 years.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### NORSE TWO eligibility criteria

> “Active primary Subfoveal Choroidal Neovascularization lesions secondary to Age-related macular degeneration (AMD) in the study eye”
> “Best corrected visual acuity of 25-67 letters read (20/50 to 20/320 Snellen equivalent)”
> “Have active leakage on Fluorescein Angiogram involving the fovea”
> “Have edema involving the fovea”
> “Be free of scarring, fibrosis, or atrophy involving the central foveal zone”
> “Previous subfoveal focal laser photocoagulation in the study eye”
> “Active intraocular inflammation (grade trace or above) in the study eye”
> “Current vitreous haemorrhage in the study eye”
> “Polypoidal choroidal vasculopathy (PCV) in the study eye”
> “Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with anti-glaucoma medication)”

Source: [ClinicalTrials.gov NCT03834753](https://clinicaltrials.gov/study/NCT03834753)

> “Treatment-naïve nAMD patients aged 50 years and older with a best-corrected distance visual acuity (BCVA) of 25 to 67 Early Treatment Diabetic Retinopathy Study (ETDRS) letters and evidence of disease activity were included.”

Source: [Rahhal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39535413/)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### NORSE TWO treatment regimens

> “Patients randomized to ONS-5010 received monthly intravitreal doses of 1.25 mg of ONS-5010, bevacizumab-vikg (Outlook Therapeutics) for 12 months. Patients randomized to ranibizumab received 0.50 mg of ranibizumab on days 0, 30, 60, 150, and 240 based on the PIER study dosing regimen.”

Source: [Rahhal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39535413/)

| Field | Quoted record |
| --- | --- |
| Bevacizumab (ONS-5010) dose | “1.25 mg, intravitreal injection” |
| Ranibizumab dose | “0.5mg, intravitreal injection” |

Source: [ClinicalTrials.gov NCT03834753](https://clinicaltrials.gov/study/NCT03834753)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using ETDRS Best Corrected Visual Acuity Gain as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary endpoint statistical result

> “Respectively, 41.7% and 23.1% of patients gained ≥ 15 letters (3 lines) of visual acuity, with a risk difference of 0.1859 [95% CI = 0.0442, 0.3086]; P = 0.0052.”

Source: [Rahhal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39535413/)

<a id="topic-3.1.1.6.1-2"></a>

###### Primary endpoint: proportion gaining 15 or more ETDRS letters at 11 months

> “Proportion of Subjects Who Gain 15 or More Letters in Best Corrected Visual Acuity (BCVA)”
> “BCVA to be assessed as letters read using the Early Treatment Diabetic Retinopathy Study (ETDRS) charts. A positive change represents an improvement in visual acuity.”

Source: [ClinicalTrials.gov NCT03834753](https://clinicaltrials.gov/study/NCT03834753)

> “The primary efficacy endpoint was the proportion of patients who gained ≥ 15 Best Corrected Visual Acuity (BCVA) letters from baseline to Month 11 as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score. The difference observed between the study drug groups was significant, in favor of LYTENAVA (see Table 2).”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-3.1.1.6.1-3"></a>

###### Secondary endpoints

> “Mean Change in the Best Corrected Visual Acuity”
> “Proportion of Participants Who Gain at Least 10 Letters in the Best Corrected Visual Acuity”
> “Proportion of Participants Who Gain at Least 5 Letters in the Best Corrected Visual Acuity”
> “Proportion of Participants Who Lose Fewer Than 15 Letters in the Best Corrected Visual Acuity”
> “Proportion of Participants With Visual-acuity Snellen Equivalent of 20/200 or Worse”

Source: [ClinicalTrials.gov NCT03834753](https://clinicaltrials.gov/study/NCT03834753)

> “The pre-specified secondary efficacy endpoint of mean change in BCVA from baseline to Month 11 favored LYTENAVA once monthly compared to ranibizumab administered once monthly for 3 months then every 3 months and is displayed over time in Figure 1.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Summary: number of trial sites

The company's own announcement of the 12-month NORSE TWO results described the trial as enrolling 228 subjects across 39 clinical trial sites in the United States.

Source: [Outlook Therapeutics NORSE TWO 12-month safety results press release (2021)](https://www.globenewswire.com/news-release/2021/09/28/2304422/0/en/Outlook-Therapeutics-Reports-New-Positive-12-Month-Safety-Data-from-Pivotal-Phase-3-NORSE-TWO-Trial.html)

<a id="topic-3.1.1.7.1-2"></a>

###### NORSE TWO participants analyzed by arm

| Field | Ranibizumab 0.5 mg Once Monthly x 3 Months then every 3 Months (N = 115) | LYTENAVA 1.25 mg Once Monthly (N = 113) |
| --- | --- | --- |
| Number of subjects, n/N (%) | “24/104 (23.1)” | “45/108 (41.7)” |
| Risk difference | | “0.1859” |
| 95% CI | | “0.0442, 0.3086” |

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-3.1.1.7.1-3"></a>

###### NORSE TWO statistical results summary

| Field | Quoted record |
| --- | --- |
| Risk difference | “0.1859” |
| 95% CI | “0.0442, 0.3086” |

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Summary: intent-to-treat and per-protocol analyses

The company's own 12-month results announcement described the primary endpoint as met in both an intent-to-treat (ITT) primary dataset (23% ranibizumab vs. 41% bevacizumab-vikg, p=0.0052) and a secondary per-protocol (PP) dataset (24% ranibizumab vs. 41% bevacizumab-vikg, p=0.04).

Source: [Outlook Therapeutics NORSE TWO 12-month safety results press release (2021)](https://www.globenewswire.com/news-release/2021/09/28/2304422/0/en/Outlook-Therapeutics-Reports-New-Positive-12-Month-Safety-Data-from-Pivotal-Phase-3-NORSE-TWO-Trial.html)

<a id="topic-3.1.1.7.2-2"></a>

###### NORSE TWO analysis set composition

> “One hundred thirteen participants were included in the ONS-5010 group and 115 participants were included in the ranibizumab group.”
> “All 228 randomized patients were included in the ITT and safety populations (113 patients in the ONS-5010 group and 115 patients in the ranibizumab group), and 163 patients were included in the PP population (85 and 78 patients in the ONS-5010 and ranibizumab groups, respectively).”

Source: [Rahhal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39535413/)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### NORSE TWO participants included in each arm

> “One hundred thirteen participants were included in the ONS-5010 group and 115 participants were included in the ranibizumab group.”

Source: [Rahhal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39535413/)

| Field | Ranibizumab 0.5 mg Once Monthly x 3 Months then every 3 Months (N = 115) | LYTENAVA 1.25 mg Once Monthly (N = 113) |
| --- | --- | --- |
| Number of subjects, n/N (%) | “24/104 (23.1)” | “45/108 (41.7)” |

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-3.1.1.8.1-2"></a>

###### Completion and reasons for discontinuation

> “A total of 228 patients were randomized at 39 study centers across the US. Of those, 198 (86.8%) completed the study. The three most frequently reported reasons for study discontinuation were withdrawal of consent (4.8%), AEs (3.5%), and other reasons (1.8%).”
> “In the ONS-5010 group, nine patients discontinued the treatment and withdrew from the study (five because of AEs, three lost to follow-up, and one withdrew voluntarily); one patient completed treatment but withdrew from the study; and two patients discontinued treatment but completed the study. In the ranibizumab group, 20 patients discontinued the treatment and withdrew from the study (10 due to voluntary withdrawal, five because of AEs, three because of lack of effectiveness, and three for other reasons); one patient discontinued treatment but completed the study.”

Source: [Rahhal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39535413/)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### NORSE TWO baseline age

> “Patient ages ranged from 54 to 98 years, with a median age of 79 years.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

> “Treatment-naïve nAMD patients aged 50 years and older with a best-corrected distance visual acuity (BCVA) of 25 to 67 Early Treatment Diabetic Retinopathy Study (ETDRS) letters and evidence of disease activity were included.”

Source: [Rahhal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39535413/)

> “In the three completed Phase 3 clinical studies, approximately 70% (238/341) of patients treated with LYTENAVA were ≥ 65 years of age and approximately 47 % (160/341) were ≥ 75 years of age. No overall differences in efficacy or safety were seen with increasing age in these studies [see Clinical Studies (14)].”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-3.1.1.8.2-2"></a>

###### NORSE TWO baseline demographics and disease characteristics

| Parameter | Ranibizumab (n = 115) | ONS-5010 (n = 113) |
| --- | --- | --- |
| Male, n (%) | “46 (40.0%)” | “46 (40.7%)” |
| Female, n (%) | “69 (60.0%)” | “67 (59.3%)” |
| Age, mean ± SD | “79.1 ± 8.49” | “78.8 ± 8.30” |
| White, n (%) | “113 (98.3%)” | “110 (97.3%)” |
| Asian, n (%) | “1 (0.9%)” | “1 (0.9%)” |
| Right study eye, n (%) | “51 (44.3%)” | “49 (43.4%)” |
| Left study eye, n (%) | “64 (55.7%)” | “64 (56.6%)” |
| Prior anti-VEGF, n (%) | “5 (4.3%)” | “4 (3.5%)” |
| Baseline BCVA, mean ± SD | “51.1 ± 12.96” | “52.1 ± 12.16” |
| Baseline CFT (μm), mean ± SD | “423.7 ± 114.77” | “430.0 ± 150.85” |

Source: [Rahhal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39535413/)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Summary: mean change in best corrected visual acuity from baseline to Month 11

The company's own 12-month results announcement reported that the secondary endpoint of mean BCVA change from baseline to Month 11 was also statistically significant, at p=0.0043 in the intent-to-treat dataset.

Source: [Outlook Therapeutics NORSE TWO 12-month safety results press release (2021)](https://www.globenewswire.com/news-release/2021/09/28/2304422/0/en/Outlook-Therapeutics-Reports-New-Positive-12-Month-Safety-Data-from-Pivotal-Phase-3-NORSE-TWO-Trial.html)

<a id="topic-3.1.1.8.3-2"></a>

###### NORSE TWO primary endpoint result

| Field | Ranibizumab 0.5 mg Once Monthly x 3 Months then every 3 Months (N = 115) | LYTENAVA 1.25 mg Once Monthly (N = 113) |
| --- | --- | --- |
| Number of subjects, n/N (%) | “24/104 (23.1)” | “45/108 (41.7)” |
| Risk difference | | “0.1859” |
| 95% CI | | “0.0442, 0.3086” |

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

> “Respectively, 41.7% and 23.1% of patients gained ≥ 15 letters (3 lines) of visual acuity, with a risk difference of 0.1859 [95% CI = 0.0442, 0.3086]; P = 0.0052. The change in BCVA from baseline to 11 months was found to be 11.2 ± 12.19 and 5.8 ± 14.80 ETDRS letters, respectively. The number of patients gaining ≥ 5 and ≥ 10 letters and patients losing < 15 letters was significantly higher in the ONS-5010 group. Similarly, patients with a Snellen visual acuity equivalent of 20/200 (35 ETDRS letters) or worse at 11 months were significantly fewer in the ONS-5010 group.”

Source: [Rahhal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39535413/)

<a id="topic-3.1.1.8.3-3"></a>

###### NORSE TWO secondary endpoint responder analysis

| Parameter, n/N (%) | Ranibizumab (n = 115) | ONS-5010 (n = 113) |
| --- | --- | --- |
| Subjects gaining ≥5 letters from baseline at 11 months | “53/104 (51.0)” | “74/108 (68.5)” |
| Subjects gaining ≥10 letters from baseline at 11 months | “36/104 (34.6)” | “61/108 (56.5)” |
| Subjects losing <15 letters from baseline at 11 months | “86/104 (82.7)” | “101/108 (93.5)” |
| Subjects with a visual acuity Snellen equivalent of 20/200 or worse at 11 months | “25/104 (24.0)” | “14/108 (13.0)” |

Source: [Rahhal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39535413/)

<a id="topic-3.1.1.8.3-4"></a>

###### NORSE TWO mean BCVA change by complementary analysis

> “When calculated using the trimmed means fixed approach, the least squares (LS) mean change in BCVA from baseline to 11 months was 19.310 letters in the ONS-5010 group and 14.575 letters in the ranibizumab group (LS mean difference of 4.735 [95% CI = 1.306, 8.163]; P = 0.0035). When calculated using the trimmed means adaptive approach, the LS mean change in BCVA from baseline to 11 months was 13.640 letters in the ONS-5010 group and 5.770 letters in the ranibizumab group. The difference observed between study treatment groups was significant, with an LS mean difference of 7.870 (95% CI = 4.536, 12.599; P = 0.0001).”

Source: [Rahhal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39535413/)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Summary: ocular adverse events and inflammation

The company's own 12-month results announcement reported only one subject with an ocular inflammation adverse event following exposure to bevacizumab-vikg, one related ocular serious adverse event in the bevacizumab-vikg arm (which resolved), and conjunctival hemorrhage as the most common ocular adverse event, and described the safety database as consistent with previously published bevacizumab safety results.

Source: [Outlook Therapeutics NORSE TWO 12-month safety results press release (2021)](https://www.globenewswire.com/news-release/2021/09/28/2304422/0/en/Outlook-Therapeutics-Reports-New-Positive-12-Month-Safety-Data-from-Pivotal-Phase-3-NORSE-TWO-Trial.html)

<a id="topic-3.1.1.8.5-2"></a>

###### NORSE TWO serious ocular adverse event and most common adverse event by arm

> “Only one patient in the ONS-5010 group had a study-related serious ocular adverse event (SAE), namely, elevated intraocular pressure. The most common adverse event in the ONS-5010 group was conjunctival hemorrhage (8.8%), and reduced visual acuity in the ranibizumab group (12.2%).”

Source: [Rahhal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39535413/)

<a id="topic-3.1.1.8.5-3"></a>

###### NORSE TWO treatment-emergent adverse event summary

| Criteria | Ranibizumab (n = 115), n (%) | ONS-5010 (n = 113), n (%) |
| --- | --- | --- |
| At least 1 TEAE | “85 (73.9%)” | “85 (75.2%)” |
| At least 1 TEAE related to study drug/study procedure | “9 (7.8%)” | “21 (18.6%)” |
| At least 1 ocular TEAE | “61 (53.0%)” | “59 (52.2%)” |
| At least 1 serious TEAE | “16 (13.9%)” | “14 (12.4%)” |
| At least 1 TEAE leading to discontinuation | “5 (4.3%)” | “2 (1.8%)” |

Source: [Rahhal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39535413/)

<a id="topic-3.1.1.8.5-4"></a>

###### NORSE TWO deaths during the study

> “A total of five patients died, including three in the ONS-5010 group and two in the ranibizumab group. The events that resulted in death were COVID-19 and respiratory failure (both occurring in the same patient of the ONS-5010 group), myocardial infarction and death due to COVID-19 (each occurring in different patients of the ONS-5010 group), and cardiac arrest and cardiac death (each occurring in different patients in the ranibizumab group). These events were not considered by the investigators to be related to the study treatment/study procedure.”

Source: [Rahhal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39535413/)

<a id="topic-3.1.1.8.5-5"></a>

###### Pooled ocular adverse reactions across the LYTENAVA clinical development program (five trials)

> “The data described below reflect exposure to LYTENAVA in 601 patients, in five clinical trials [see Clinical Studies (14)].”
> “Table 1 shows the most common ocular adverse reactions in LYTENAVA treated patients compared with ranibizumab 0.5 mg.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

| Adverse Reactions | LYTENAVA 1.25 mg (N = 601) | Ranibizumab 0.5 mg (N = 345) |
| --- | --- | --- |
| Conjunctival hemorrhage | “4%” | “3%” |
| Eye pain | “2%” | “1%” |
| Vitreous floaters | “2%” | “1%” |

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

> “Less common ocular adverse reactions reported in the study eye in <1% of patients treated with LYTENAVA were corneal abrasion, dry eye, eye irritation, and intraocular pressure increased.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary: comparator dosing regimen

NORSE TWO compared monthly LYTENAVA dosing for one year against a ranibizumab regimen of three monthly loading doses followed by quarterly dosing, rather than against monthly ranibizumab throughout the study.

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-3.1.1.9-2"></a>

###### Authors' rationale for the unequal dosing regimens

> “The different dosing regimen between the two groups is not considered a limitation of the study given that the aim of the study was to demonstrate the effect of bevacizumab. One reason for spacing doses in the ranibizumab group was to replicate a more realistic clinical dosing schedule. Furthermore, according to both the IVAN and CATT study, spaced dosing of ranibizumab was shown to be as effective as monthly dosing.”
> “While clinicians often treat nAMD with greater frequency than the ranibizumab arm of the NORSE TWO study, the study was designed to meet a regulatory endpoint of comparison to a previously approved treatment dosing regimen in order to demonstrate the existence of a treatment effect for ONS-5010.”

Source: [Rahhal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39535413/)

<a id="topic-3.1.1.9-3"></a>

###### Greater injection frequency as a possible driver of the higher treatment-related adverse event rate

> “The frequency of TEAEs considered by the investigators to be related to the study treatment/study procedure was greater in the ONS-5010 group compared with the ranibizumab group (18.6% [21 patients] vs 7.8% [9 patients]). Hypothetically, this may be due to a greater number of injections in the ONS-5010 group (12 injections in the ONS-5010 group versus five injections in the ranibizumab group).”

Source: [Rahhal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39535413/)

<a id="heading-3.1.2"></a>

#### 3.1.2 NORSE EIGHT

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Second pivotal trial supporting the NORSE TWO efficacy finding

> “In a multicenter, randomized, masked, controlled study (NORSE EIGHT – NCT06190093), 400 adult patients with nAMD were randomized (1:1) to LYTENAVA 1.25 mg or ranibizumab 0.5 mg, administered every 4 weeks for 3 total doses (Day 0, Week 4, and Week 8). The primary efficacy endpoint was the mean change in baseline BCVA as measured by ETDRS score at Week 8 using a non-inferiority (NI) margin of -3.5 letters.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

> “Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects With Neovascular Age-related Macular Degeneration; NORSE EIGHT”

Source: [ClinicalTrials.gov NCT06190093](https://clinicaltrials.gov/study/NCT06190093)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### NORSE EIGHT trial dates and location

| Field | Quoted record |
| --- | --- |
| Study Start Date | “2024-01-24” |
| Primary Completion Date | “2024-11-07” |
| Study Completion Date | “2024-12-05” |
| Overall Status | “Completed” |
| Country | “United States” |

Source: [ClinicalTrials.gov NCT06190093](https://clinicaltrials.gov/study/NCT06190093)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### NORSE EIGHT study design

| Field | Quoted record |
| --- | --- |
| Allocation | “N/A” |
| Intervention Model | “Parallel Assignment” |
| Masking | “Triple” |
| Who Masked | “Participant”, “Investigator”, “Outcomes Assessor” |
| Primary Purpose | “Treatment” |
| Phase | “Phase 3” |
| Enrollment | “400” |

Source: [ClinicalTrials.gov NCT06190093](https://clinicaltrials.gov/study/NCT06190093)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### NORSE EIGHT eligibility criteria

> “Active primary Subfoveal Choroidal Neovascularization lesions secondary to Age-related macular degeneration (AMD) in the study eye”
> “Best corrected visual acuity of 35-75 letters read (20/32 to 20/200 Snellen equivalent)”
> “Have active leakage on Fluorescein Angiogram involving the fovea”
> “Have edema involving the fovea”
> “Be free of scarring, fibrosis, or atrophy involving the central foveal zone”
> “Current vitreous hemorrhage in the study eye”
> “Polypoidal choroidal vasculopathy (PCV) in the study eye”
> “Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with anti-glaucoma medication)”

Source: [ClinicalTrials.gov NCT06190093](https://clinicaltrials.gov/study/NCT06190093)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### NORSE EIGHT treatment regimens

| Field | Quoted record |
| --- | --- |
| ONS-5010 bevacizumab dose | “1.25 mg, intravitreal injection” |
| Ranibizumab dose | “0.5mg, intravitreal injection” |

Source: [ClinicalTrials.gov NCT06190093](https://clinicaltrials.gov/study/NCT06190093)

> “In a multicenter, randomized, masked, controlled study (NORSE EIGHT – NCT06190093), 400 adult patients with nAMD were randomized (1:1) to LYTENAVA 1.25 mg or ranibizumab 0.5 mg, administered every 4 weeks for 3 total doses (Day 0, Week 4, and Week 8).”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Mean Change in ETDRS Best Corrected Visual Acuity as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary endpoint design as a non-inferiority comparison

> “The primary efficacy endpoint was the mean change in baseline BCVA as measured by ETDRS score at Week 8 using a non-inferiority (NI) margin of -3.5 letters.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-3.1.2.6.1-2"></a>

###### Primary endpoint: mean change in ETDRS BCVA from baseline at Week 8

> “Evaluate the Effectiveness of Intravitreal Injections of ONS-5010 Compared to Ranibizumab in Preventing Vision Loss, as Measured by the Mean Change in Baseline Best Correct Visual Acuity (BCVA) at Week 8”
> “BCVA to be assessed as letters read using the Early Treatment Diabetic Retinopathy Study (ETDRS) charts. A positive change represents an improvement in visual acuity.”

Source: [ClinicalTrials.gov NCT06190093](https://clinicaltrials.gov/study/NCT06190093)

> “The primary efficacy endpoint was the mean change in baseline BCVA as measured by ETDRS score at Week 8 using a non-inferiority (NI) margin of -3.5 letters.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-3.1.2.6.1-3"></a>

###### Anatomic (pharmacodynamic) outcome: central retinal/foveal thickness

> “Changes in CFT were assessed using optical coherence tomography in NORSE TWO and NORSE EIGHT [see Clinical Studies (14)]. Increasingly greater reductions in CFT were observed at Weeks 4, 8, and 12 across both treatment arms. Anatomic data were not used to influence LYTENAVA treatment decisions.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### NORSE EIGHT enrollment and randomization

> “In a multicenter, randomized, masked, controlled study (NORSE EIGHT – NCT06190093), 400 adult patients with nAMD were randomized (1:1) to LYTENAVA 1.25 mg or ranibizumab 0.5 mg”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-3.1.2.7.1-2"></a>

###### NORSE EIGHT non-inferiority result

> “NORSE EIGHT did not meet its pre-specified NI margin of -3.5 letters in mean change from baseline BCVA at Week 8 compared to ranibizumab.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Summary: baseline visual acuity

The LYTENAVA arm had a mean baseline BCVA of 58.8 ETDRS letters.

Source: [Outlook Therapeutics NORSE EIGHT presentation press release (2025)](https://www.biospace.com/press-releases/outlook-therapeutics-announces-presentation-of-efficacy-and-safety-results-from-norse-eight-clinical-trial-evaluating-ons-5010-for-the-treatment-of-wet-amd)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Summary: preliminary topline Week 8 result (November 2024 announcement)

Before the label's final analysis, the company's preliminary topline announcement reported a mean BCVA increase of “+4.2 letters” for ONS-5010 versus “+6.3 letters” for ranibizumab at Week 8, a difference it described as “-2.257 BCVA letters” (95% CI -4.044, -0.470); these preliminary figures differ slightly from the final Week 8 result in the approved label (Section 3.1.2.8.3 above).

Source: [Outlook Therapeutics NORSE EIGHT preliminary topline results press release (2024)](https://www.sec.gov/Archives/edgar/data/1649989/000110465924123554/tm2429443d1_ex99-1.htm)

<a id="topic-3.1.2.8.3-2"></a>

###### Summary: BCVA gains over time and anatomic response

Mean BCVA improved progressively from baseline for the LYTENAVA arm: approximately +3.3 letters at month 1 (week 4), +4.2 letters at month 2 (week 8), and +5.5 letters at month 3 (week 12). Central retinal thickness decreased by approximately 123.9 microns in the LYTENAVA arm and 127.3 microns in the ranibizumab arm at week 12, an anatomic response the companies described as comparable between arms.

Source: [Outlook Therapeutics NORSE EIGHT complete twelve-week results press release (2025)](https://www.globenewswire.com/news-release/2025/01/16/3010622/0/en/Outlook-Therapeutics-Announces-Complete-Twelve-Week-Efficacy-and-Safety-Results-of-NORSE-EIGHT-Clinical-Trial.html); [Outlook Therapeutics NORSE EIGHT presentation press release (2025)](https://www.biospace.com/press-releases/outlook-therapeutics-announces-presentation-of-efficacy-and-safety-results-from-norse-eight-clinical-trial-evaluating-ons-5010-for-the-treatment-of-wet-amd)

<a id="topic-3.1.2.8.3-3"></a>

###### NORSE EIGHT week 8 BCVA result

> “At Week 8, the LYTENAVA group had a mean increase in BCVA of 3.3 compared to a mean increase of 4.5 in the ranibizumab group. The LS mean difference and 95% CI was -2.3 (-4.0, -0.5). LYTENAVA showed an increase from baseline in BCVA at Week 12 consistent with NORSE TWO.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

> “At Week 8, the LYTENAVA group had a mean increase in BCVA of 3.3 compared to a mean increase of 4.5 in the ranibizumab group.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-3.1.2.8.3-4"></a>

###### Week 12 visual acuity (non-primary timepoint)

> “The difference in mean BCVA between ONS-5010 and ranibizumab was -1.009 letters (95% confidence interval, -2.865, 0.848), meeting the noninferiority margin at Month 3 (p=0.0043)”

Source: [Outlook Therapeutics NORSE EIGHT presentation press release (2025)](https://www.biospace.com/press-releases/outlook-therapeutics-announces-presentation-of-efficacy-and-safety-results-from-norse-eight-clinical-trial-evaluating-ons-5010-for-the-treatment-of-wet-amd)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### NORSE EIGHT ocular adverse events

> “ONS-5010 was generally well-tolerated with overall ocular adverse event rates comparable to ranibizumab.”
> “no cases of retinal vasculitis reported in either study arm”

Source: [Outlook Therapeutics NORSE EIGHT preliminary topline results press release (2024)](https://www.sec.gov/Archives/edgar/data/1649989/000110465924123554/tm2429443d1_ex99-1.htm)

> “consistent with previously reported safety results from the NORSE ONE, NORSE TWO, and NORSE THREE clinical trials”

Source: [Outlook Therapeutics NORSE EIGHT complete twelve-week results press release (2025)](https://www.globenewswire.com/news-release/2025/01/16/3010622/0/en/Outlook-Therapeutics-Announces-Complete-Twelve-Week-Efficacy-and-Safety-Results-of-NORSE-EIGHT-Clinical-Trial.html)

<a id="topic-3.1.2.8.5-2"></a>

###### Pooled ocular adverse reactions across the LYTENAVA clinical development program (five trials)

| Adverse Reactions | LYTENAVA 1.25 mg (N = 601) | Ranibizumab 0.5 mg (N = 345) |
| --- | --- | --- |
| Conjunctival hemorrhage | “4%” | “3%” |
| Eye pain | “2%” | “1%” |
| Vitreous floaters | “2%” | “1%” |

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary: primary endpoint not met at the pre-specified timepoint

NORSE EIGHT did not meet its pre-specified non-inferiority margin of -3.5 letters for the primary endpoint of mean change in BCVA at Week 8, although the LS mean difference at Week 12 (a secondary, non-primary timepoint) was within the non-inferiority margin.

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="heading-3.1.3"></a>

#### 3.1.3 NORSE ONE

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### NORSE ONE trial title and design

> “A Clinical Effectiveness, Multicenter, Randomized, Double-masked, Controlled Study of the Efficacy and Safety of ONS-5010 in Subjects With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration”

Source: [ClinicalTrials.gov NCT03844074](https://clinicaltrials.gov/study/NCT03844074)

> “NORSE 1 enrolled a total of 61 treatment-naïve and previously treated patients diagnosed with wet AMD”
> “The NORSE 1 clinical trial is a small 30-subject-per-arm clinical experience trial”

Source: [Outlook Therapeutics NORSE ONE topline results press release (2020)](https://www.globenewswire.com/news-release/2020/08/26/2084007/0/en/Outlook-Therapeutics-Reports-Topline-Results-and-Positive-Proof-of-Concept-for-ONS-5010-LYTENAVA-bevacizumab-vikg-from-NORSE-1.html)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### NORSE ONE trial dates and location

| Field | Quoted record |
| --- | --- |
| Study Start Date | “2018-10-01” |
| Primary Completion Date | “2020-07-23” |
| Study Completion Date | “2020-08-13” |
| Overall Status | “Completed” |
| Country | “Australia” |

Source: [ClinicalTrials.gov NCT03844074](https://clinicaltrials.gov/study/NCT03844074)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### NORSE ONE study design

| Field | Quoted record |
| --- | --- |
| Allocation | “Randomized” |
| Intervention Model | “Parallel Assignment” |
| Masking | “Double” |
| Who Masked | “Participant”, “Outcomes Assessor” |
| Primary Purpose | “Treatment” |
| Phase | “Phase 3” |
| Enrollment | “61” |

Source: [ClinicalTrials.gov NCT03844074](https://clinicaltrials.gov/study/NCT03844074)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### NORSE ONE eligibility criteria

> “Active primary or recurrent Subfoveal Choroidal Neovascularization lesions secondary to Age-related macular degeneration (AMD) in the study eye”
> “Best corrected visual acuity of 20/40 to 20/320”
> “Have active leakage on Fluorescein Angiogram involving the fovea”
> “Have edema involving the fovea”
> “Be free of foveal scarring”
> “Be free of foveal atrophy”
> “Previous use of anti-VEGF or bevacizumab within 6 weeks”
> “Polypoidal choroidal vasculopathy (PCV) confirmed by indocyanine green angiography (ICGA)”
> “Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with anti-glaucoma medication)”

Source: [ClinicalTrials.gov NCT03844074](https://clinicaltrials.gov/study/NCT03844074)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### NORSE ONE treatment regimens

| Field | Quoted record |
| --- | --- |
| Bevacizumab (ONS-5010) dose | “1.25 mg, intravitreal injection” |
| Ranibizumab dose | “0.5mg, intravitreal injection” |

Source: [ClinicalTrials.gov NCT03844074](https://clinicaltrials.gov/study/NCT03844074)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using ETDRS Best Corrected Visual Acuity Gain as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### NORSE ONE primary endpoint definition

> “Proportion of subjects who gain 15 or more letters in the best corrected visual acuity (BCVA) score”

Source: [ClinicalTrials.gov NCT03844074](https://clinicaltrials.gov/study/NCT03844074)

<a id="topic-3.1.3.6.1-2"></a>

###### NORSE ONE primary and secondary outcome measures

> “Proportion of subjects who gain 15 or more letters in the best corrected visual acuity (BCVA) score”
> “BCVA to be assessed as letters read using the Early Treatment Diabetic Retinopathy Study (ETDRS) charts. A positive change represents an improvement in visual acuity.”

Source: [ClinicalTrials.gov NCT03844074](https://clinicaltrials.gov/study/NCT03844074)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Summary: participants analyzed per arm

The company's topline results announcement described the ONS-5010 arm as 25 patients and the ranibizumab arm as 23 patients within the 61-patient trial.

Source: [Outlook Therapeutics NORSE ONE topline results press release (2020)](https://www.globenewswire.com/news-release/2020/08/26/2084007/0/en/Outlook-Therapeutics-Reports-Topline-Results-and-Positive-Proof-of-Concept-for-ONS-5010-LYTENAVA-bevacizumab-vikg-from-NORSE-1.html)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### NORSE ONE enrollment

> “NORSE 1 enrolled a total of 61 treatment-naïve and previously treated patients diagnosed with wet AMD”
> “The NORSE 1 clinical trial is a small 30-subject-per-arm clinical experience trial”

Source: [Outlook Therapeutics NORSE ONE topline results press release (2020)](https://www.globenewswire.com/news-release/2020/08/26/2084007/0/en/Outlook-Therapeutics-Reports-Topline-Results-and-Positive-Proof-of-Concept-for-ONS-5010-LYTENAVA-bevacizumab-vikg-from-NORSE-1.html)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Summary: proportion gaining 15 or more letters at Month 11

The company's topline results announcement reported that 2 of 25 (8%) patients on the ONS-5010 arm and 5 of 23 (22%) patients on the ranibizumab arm gained more than 15 letters of best corrected visual acuity at Month 11, favoring ranibizumab numerically in this small trial.

Source: [Outlook Therapeutics NORSE ONE topline results press release (2020)](https://www.globenewswire.com/news-release/2020/08/26/2084007/0/en/Outlook-Therapeutics-Reports-Topline-Results-and-Positive-Proof-of-Concept-for-ONS-5010-LYTENAVA-bevacizumab-vikg-from-NORSE-1.html)

<a id="topic-3.1.3.8.3-2"></a>

###### Summary: treatment-naive subgroup

Among treatment-naive participants, the announcement reported 2 of 6 (33%) patients on the ONS-5010 arm and 4 of 13 (31%) patients on the ranibizumab arm gaining more than 15 letters at Month 11.

Source: [Outlook Therapeutics NORSE ONE topline results press release (2020)](https://www.globenewswire.com/news-release/2020/08/26/2084007/0/en/Outlook-Therapeutics-Reports-Topline-Results-and-Positive-Proof-of-Concept-for-ONS-5010-LYTENAVA-bevacizumab-vikg-from-NORSE-1.html)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Summary: safety comparable between arms

The company's topline results announcement reported no statistical differences in safety between ranibizumab and ONS-5010, and zero cases of ocular inflammation.

Source: [Outlook Therapeutics NORSE ONE topline results press release (2020)](https://www.globenewswire.com/news-release/2020/08/26/2084007/0/en/Outlook-Therapeutics-Reports-Topline-Results-and-Positive-Proof-of-Concept-for-ONS-5010-LYTENAVA-bevacizumab-vikg-from-NORSE-1.html)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary: small comparator trial with results diverging from NORSE TWO

NORSE ONE was a small, 61-patient clinical experience trial in Australia, roughly 30 subjects per arm, in which a numerically smaller proportion of the ONS-5010 arm than the ranibizumab arm gained 15 or more letters, a result not repeated in the larger pivotal NORSE TWO trial.

Source: [Outlook Therapeutics NORSE ONE topline results press release (2020)](https://www.globenewswire.com/news-release/2020/08/26/2084007/0/en/Outlook-Therapeutics-Reports-Topline-Results-and-Positive-Proof-of-Concept-for-ONS-5010-LYTENAVA-bevacizumab-vikg-from-NORSE-1.html)

<a id="heading-3.1.4"></a>

#### 3.1.4 NORSE THREE

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Summary: purpose of the trial

The company's safety results announcement described NORSE THREE as an open-label safety study conducted to ensure an adequate number of safety exposures to ONS-5010 were available for the initial BLA submission to the FDA.

Source: [Outlook Therapeutics NORSE THREE safety results press release (2021)](https://www.globenewswire.com/news-release/2021/03/31/2202384/0/en/Outlook-Therapeutics-Reports-Positive-Safety-Profile-from-NORSE-THREE-Open-Label-Safety-Study-for-ONS-5010-LYTENAVA-bevacizumab-vikg.html)

<a id="topic-3.1.4.1-2"></a>

###### NORSE THREE trial title

> “A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders, NORSE THREE”

Source: [ClinicalTrials.gov NCT04516278](https://clinicaltrials.gov/study/NCT04516278)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### NORSE THREE trial dates and location

| Field | Quoted record |
| --- | --- |
| Study Start Date | “2020-10-01” |
| Primary Completion Date | “2021-02-10” |
| Study Completion Date | “2021-02-10” |
| Overall Status | “Completed” |
| Country | “United States” |

Source: [ClinicalTrials.gov NCT04516278](https://clinicaltrials.gov/study/NCT04516278)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Summary: enrollment and disease mix

The company's safety results announcement described NORSE THREE as enrolling 197 treatment-naive and previously treated subjects with wet AMD, diabetic macular edema (DME), or branch retinal vein occlusion (BRVO), to add safety exposures ahead of the initial BLA submission.

Source: [Outlook Therapeutics NORSE THREE safety results press release (2021)](https://www.globenewswire.com/news-release/2021/03/31/2202384/0/en/Outlook-Therapeutics-Reports-Positive-Safety-Profile-from-NORSE-THREE-Open-Label-Safety-Study-for-ONS-5010-LYTENAVA-bevacizumab-vikg.html)

<a id="topic-3.1.4.3-2"></a>

###### NORSE THREE study design

| Field | Quoted record |
| --- | --- |
| Allocation | “N/A” |
| Intervention Model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Primary Purpose | “Treatment” |
| Phase | “Phase 3” |
| Enrollment | “197” |

Source: [ClinicalTrials.gov NCT04516278](https://clinicaltrials.gov/study/NCT04516278)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### NORSE THREE eligibility criteria

> “Active clinical diagnosis and OCT confirmation of one of the following retinal disorders: exudative age-related macular degeneration (AMD), diabetic macular edema (DME), or branch retinal vein occlusion (BRVO) and, in the opinion of the Investigator, requires treatment with an anti-VEGF therapy”
> “Previous use of approved anti-VEGF or Avastin® within 4 weeks preceding randomization”
> “History of inadequate response to previous intravitreal anti-VEGF therapy”
> “Active intraocular inflammation in the study eye”
> “Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with anti-glaucoma medication)”

Source: [ClinicalTrials.gov NCT04516278](https://clinicaltrials.gov/study/NCT04516278)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### NORSE THREE treatment regimen

| Field | Quoted record |
| --- | --- |
| Bevacizumab (ONS-5010) dose | “1.25 mg, intravitreal injection” |

Source: [ClinicalTrials.gov NCT04516278](https://clinicaltrials.gov/study/NCT04516278)

> “Subjects enrolled in the study received three monthly intravitreal doses of ONS-5010 / LYTENAVA™.”

Source: [Outlook Therapeutics NORSE THREE safety results press release (2021)](https://www.globenewswire.com/news-release/2021/03/31/2202384/0/en/Outlook-Therapeutics-Reports-Positive-Safety-Profile-from-NORSE-THREE-Open-Label-Safety-Study-for-ONS-5010-LYTENAVA-bevacizumab-vikg.html)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Adverse Event Incidence as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### NORSE THREE primary outcome measure

> “Number of Participants With Adverse Events”

Source: [ClinicalTrials.gov NCT04516278](https://clinicaltrials.gov/study/NCT04516278)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Summary: enrollment

The company's safety results announcement described NORSE THREE as enrolling 197 treatment-naive and previously treated subjects.

Source: [Outlook Therapeutics NORSE THREE safety results press release (2021)](https://www.globenewswire.com/news-release/2021/03/31/2202384/0/en/Outlook-Therapeutics-Reports-Positive-Safety-Profile-from-NORSE-THREE-Open-Label-Safety-Study-for-ONS-5010-LYTENAVA-bevacizumab-vikg.html)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Summary: enrollment and adverse event incidence

The company's safety results announcement reported that 20 of the 197 enrolled patients (10%) experienced an adverse event in the study eye, most commonly associated with the injection procedure rather than the drug itself.

Source: [Outlook Therapeutics NORSE THREE safety results press release (2021)](https://www.globenewswire.com/news-release/2021/03/31/2202384/0/en/Outlook-Therapeutics-Reports-Positive-Safety-Profile-from-NORSE-THREE-Open-Label-Safety-Study-for-ONS-5010-LYTENAVA-bevacizumab-vikg.html)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

Not applicable.

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Summary: adverse event incidence and comparison to prior bevacizumab safety data

Of the 197 enrolled patients, 20 (10%) experienced an adverse event in the study eye, most commonly associated with the injection procedure. The company described the safety profile as showing no unexpected trends and as consistent with prior published bevacizumab safety data, including the 2011 CATT study.

Source: [Outlook Therapeutics NORSE THREE safety results press release (2021)](https://www.globenewswire.com/news-release/2021/03/31/2202384/0/en/Outlook-Therapeutics-Reports-Positive-Safety-Profile-from-NORSE-THREE-Open-Label-Safety-Study-for-ONS-5010-LYTENAVA-bevacizumab-vikg.html)

<a id="topic-3.1.4.8.5-2"></a>

###### NORSE THREE absence of serious adverse events

> “There were no serious adverse events associated with treatment”
> “zero cases of ocular inflammation, a concern that has emerged for other anti-VEGF (Vascular Endothelial Growth Factor) therapies”

Source: [Outlook Therapeutics NORSE THREE safety results press release (2021)](https://www.globenewswire.com/news-release/2021/03/31/2202384/0/en/Outlook-Therapeutics-Reports-Positive-Safety-Profile-from-NORSE-THREE-Open-Label-Safety-Study-for-ONS-5010-LYTENAVA-bevacizumab-vikg.html)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary: open-label, single-arm design

NORSE THREE had no comparator or masking, so its adverse-event findings cannot be compared statistically with a control arm; it was designed only to add safety exposures to the overall LYTENAVA safety database ahead of the initial BLA submission.

Source: [ClinicalTrials.gov NCT04516278](https://clinicaltrials.gov/study/NCT04516278); [Outlook Therapeutics NORSE THREE safety results press release (2021)](https://www.globenewswire.com/news-release/2021/03/31/2202384/0/en/Outlook-Therapeutics-Reports-Positive-Safety-Profile-from-NORSE-THREE-Open-Label-Safety-Study-for-ONS-5010-LYTENAVA-bevacizumab-vikg.html)

<a id="heading-3.1.5"></a>

#### 3.1.5 NORSE SEVEN

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### NORSE SEVEN trial title

> “A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus PFS in Subjects With Visual Impairment Due to Retinal Disorders, NORSE SEVEN”

Source: [ClinicalTrials.gov NCT05112861](https://clinicaltrials.gov/study/NCT05112861)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### NORSE SEVEN trial dates and location

| Field | Quoted record |
| --- | --- |
| Study Start Date | “2021-11-15” |
| Primary Completion Date | “2027-12” |
| Study Completion Date | “2027-12” |
| Overall Status | “Active, not recruiting” |
| Country | “United States” |

Source: [ClinicalTrials.gov NCT05112861](https://clinicaltrials.gov/study/NCT05112861)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### NORSE SEVEN study design

| Field | Quoted record |
| --- | --- |
| Allocation | “N/A” |
| Intervention Model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Primary Purpose | “Treatment” |
| Phase | “Phase 3” |
| Enrollment | “120” |

Source: [ClinicalTrials.gov NCT05112861](https://clinicaltrials.gov/study/NCT05112861)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### NORSE SEVEN eligibility criteria

> “Active clinical diagnosis and OCT confirmation of one of the following retinal disorders: exudative age-related macular degeneration (AMD), diabetic macular edema (DME), or branch retinal vein occlusion (BRVO) and, in the opinion of the Investigator, requires treatment with an anti-VEGF therapy”
> “Previous use of approved anti-VEGF or Avastin® within 4 weeks preceding randomization”
> “Previous use of Beovu®”
> “History of inadequate response to previous intravitreal anti-VEGF therapy”
> “Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with anti-glaucoma medication)”

Source: [ClinicalTrials.gov NCT05112861](https://clinicaltrials.gov/study/NCT05112861)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### NORSE SEVEN treatment regimen

| Field | Quoted record |
| --- | --- |
| Bevacizumab (ONS-5010) dose | “1.25 mg, intravitreal injection” |

Source: [ClinicalTrials.gov NCT05112861](https://clinicaltrials.gov/study/NCT05112861)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Adverse Event Incidence as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### NORSE SEVEN primary outcome measure

> “Frequency and incidence of treatment-emergent adverse events following intravitreal injections of ONS-5010 in vials or PFS”

Source: [ClinicalTrials.gov NCT05112861](https://clinicaltrials.gov/study/NCT05112861)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### NORSE SEVEN planned enrollment

| Field | Quoted record |
| --- | --- |
| Enrollment | “120” |

Source: [ClinicalTrials.gov NCT05112861](https://clinicaltrials.gov/study/NCT05112861)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

Not applicable.

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

No evidence found.

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary: ongoing, single-arm bridging study

NORSE SEVEN is a single-arm, open-label study comparing ONS-5010 supplied in vials versus a pre-filled syringe, with no ranibizumab or placebo comparator; ClinicalTrials.gov lists the trial as active, not recruiting, with an estimated primary completion date of December 2027, so its results are not yet available.

Source: [ClinicalTrials.gov NCT05112861](https://clinicaltrials.gov/study/NCT05112861)

## Related pages
- [Lytenava (bevacizumab-vikg): Neovascular age-related macular degeneration](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Lytenava (bevacizumab-vikg): Neovascular age-related macular degeneration](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/executive-summary.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/economics.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: References](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/references.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: drug evaluation](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/oregon) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/oregon.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: new drug review](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/review) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/review.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: prevalence by geography](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/prevalence) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/prevalence.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/cost-effectiveness-analyses.md)
